Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis
Lisa A. Beck(University of Rochester Medicine), Ainara Rodríguez Marco(Sanofi (Spain)), Zhen Chen(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Joseph Zahn(Regeneron (United States)), Mark Boguniewicz(University of Colorado Denver), Antonella Muraro(University of Padua)
Cited by 25
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
|Journal of Allergy and Clinical Immunology|2006|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k